AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04844645 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: conventional pharmaceutical care
Description: conventional pharmaceutical care
Study NCT05444023 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pubocervical fascia reconstruction
Description: Suturing type techniques on pubocervical fascia reconstruction at anterior compartment defects.
Study NCT05444023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pubocervical fascia reconstruction
Description: Suturing type techniques on pubocervical fascia reconstruction at anterior compartment defects.
Study NCT06161727 — intervention group
Intervention type: OTHER
Intervention: HPV exposure
Description: According to group descriptions
Study NCT05594134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automatic toothbrush with nylon bristle
Description: The automatic toothbrush with nylon bristles will be used for 10 seconds per dental arch
Study NCT05594134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automatic toothbrush with silicone bristle
Description: The automatic toothbrush with silicone bristles will be used for 10 seconds
Study NCT05594134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual toothbrush used for 2 minutes
Description: A conventional manual toothbrush will be used for 2 minutes
Study NCT05594134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual toothbrush used for 45 seconds
Description: A conventional manual toothbrush will be used for 45 seconds
Study NCT05743387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: T2D care package
Description: T2D care package including lifestyle counselling, firstline antidiabetic (metformin) and lipid-lowering (statin) treatment for uncomplicated T2D and treatment support and regular check-ups for complicated T2D at village-level. Guidance will be provided via the ComBaCaL app. In case of complicated disease referral to the closest health facility for further management.
Study NCT05743387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referral to the responsible health facility
Description: CC-VHWs will refer participants to the responsible health facility for therapeutic management. The ComBaCaL app supports clinical decision making and documentation for screening, diagnosis and referral, but not prescription/provision and monitoring of antidiabetic or lipid-lowering medication for uncomplicated T2D patients or treatment support for complicated T2D patients.
Study NCT05349227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Health Coaching Program
Description: Coaching consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
Study NCT05349227 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Digital Health Coaching Program
Description: Coaching consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
Study NCT05349227 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Device: Fitbit A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
Study NCT05349227 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fitbit
Description: Device: Fitbit A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
Study NCT06470984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Professional development program provided online to small groups of professional nurse leaders via an educational platform over a 6-week period.
Study NCT06437925 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic ayran drink
Description: The test group has received probiotic ayran drink for 6 weeks
Study NCT06437925 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ayran drink
Description: The control group has received placebo ayran drink for 6 weeks
Study NCT05646368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Formulation #1
Description: Subject will receive a single dose of formulation #1 of a multivitamin/mineral supplement
Study NCT05646368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Formulation #2
Description: Subject will receive a single dose of formulation #2 of a multivitamin/mineral supplement
Study NCT06241911 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcutaneous auricular vagus nerve stimulation
Description: Transcutaneous auricular vagus nerve stimulation (tVNS) is a newly developed treatment for neuromodulation. It offers advantages such as being non-invasive, cost-effective, and not requiring battery changes, unlike invasive vagus nerve stimulation (iVNS). The auricular branch of the vagus nerve, which is the only afferent branch distributed on the surface of the human body, can be directly stimulated to produce effects similar to classic vagus nerve stimulation (VNS)
Study NCT06241911 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous auricular vagus nerve stimulation
Description: Transcutaneous auricular vagus nerve stimulation (tVNS) is a newly developed treatment for neuromodulation. It offers advantages such as being non-invasive, cost-effective, and not requiring battery changes, unlike invasive vagus nerve stimulation (iVNS). The auricular branch of the vagus nerve, which is the only afferent branch distributed on the surface of the human body, can be directly stimulated to produce effects similar to classic vagus nerve stimulation (VNS)
Study NCT05469126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.
Study NCT05469126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Administered orally.
Study NCT06053385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Melatonin sleep lotion
Description: 7 g of lotion applied to hands and arms one hour before bedtime
Study NCT06053385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo control lotion
Description: 7 g of lotion applied to hands and arms one hour before bedtime
Study NCT04423471 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sociodemographic variables
Description: * Sociodemographic variables: Sex / Age / Marital status / Level of studies completed / Employment status.~* General clinical variables: Body mass index (BMI), Medical comorbidities and Charlson Comorbidity Index, Active drug treatments~* Clinical psoriasis variables: BSA, PASI, ScalpPASI, PPPASI, DLQI, time since the diagnosis of psoriasis, previous treatments for psoriasis.~* Clinical depression variables: Psychiatric diagnoses according to clinical interview and DSM-5 criteria, age of onset and time of evolution from the first episode of major depression, time of evolution of the current episode of major depression, previous treatments for depression.~* Psychopathological variables: HADS, PHQ-9, MADRS, GAD-7, SHAPS, The Irritability Questionnaire, PSS, FSS, MoCA.~* Immunological and biochemical variables: Acute phase biomarkers, Proinflammatory cytokines, Anti-inflammatory cytokines, HPA axis, Microglia activation, Neurogenesis.~* Result variables: Changes in PASI or MADRS scores
Study NCT05938712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG
Description: Semaglutide subcutaneous once weekly for 12 weeks.
Study NCT05938712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide, 1.0 mg/mL
Description: Dapagliflozin oral once daily for 12 weeks.
Study NCT06256237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS004
Description: Specified dose on specified days.
Study NCT06256237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Specified dose on specified days.
Study NCT06256237 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: Patients with resectable tumors after neoadjuvant therapy will be treated with surgery.
Study NCT06256237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Specified dose on specified days.
Study NCT06256237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum
Description: Specified dose on specified days.
Study NCT05327816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV preF-based Vaccine
Description: RSV preF-based vaccine will be administered as intramuscular injection.
Study NCT06202846 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cfDNA analysis
Description: In order to compare the performance of the ctDNA test with techniques used in routine diagnostics, we will compare the results obtained by the ctDNA test with those obtained by FISH.~compare the results obtained by the ctDNA test and FISH. This will enable us to identify a potential diagnostic gain. We will compare the percentage of patients for whom a positive test result result was obtained by the lncDNA test (Y chromosome detection) to the percentage of patients for whom a positive result was obtained by FISH.
Study NCT06207955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TMJ Arthrocentesis Followed By Injectable Platelet Rich Fibrin And Botulinum Toxin Type A
Description: TMJ Arthrocentesis I-PRF Intra-articular Injection Botulinum Toxin Type A to Lateral Pterygoid Muscle
Study NCT06207955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TMJ Arthrocentesis Followed By Injectable Platelet Rich Fibrin
Description: TMJ Arthrocentesis I-PRF Intra-articular Injection
Study NCT06207955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TMJ Arthrocentesis
Description: TMJ Arthrocentesis By Saline
Study NCT04593381 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: All patients accrued will be treated with SBRT to all sites of active metastatic disease as per CT scan or PET/CT and/or MRI. A range of schedules and doses are provided, it is advised that the maximum dose that can be achieved whilst meeting the organs at risk planning constraints is prescribed.
Study NCT05327816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as intramuscular injection.
Study NCT05308706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8 weeks of home based use.
Description: Use of the devices for an 8 week study period. Devices are preset to follow a scheduled activation pattern during the day.
Study NCT05308706 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 8 weeks of home based use.
Description: Use of the devices for an 8 week study period. Devices are preset to follow a scheduled activation pattern during the day.
Study NCT05059678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care
Study NCT05059678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational materials and attend videoconference sessions
Study NCT05059678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05059678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05027035 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: surgical plication or nocturnal non-invasive ventilation
Description: 10 participants for surgical plication and 10 participants for nocturnal non-invasive ventilation.
Study NCT05527262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Queen Square Upper Limb Neurorehabilitation Programme
Description: A timetable will be implemented including a minimum of 45 hours of active time on task over 3 weeks 5-days a week (first and last day will involve the assessment procedures) (timetabled, 90-hours). Our unpublished in-service audits suggest that this equates to 45-60 hours of active upper limb training. The remainder of the time is spent on rest (in-session, between-session), cardiovascular fitness, and education (promoting self-efficacy). The programme is staffed with a 1:1 staff/patient ratio (4 physiotherapists, 4 occupational therapists, 4 rehabilitation assistants for 12 patients at any one time). Participants in this trial will receive two daily sessions each of physiotherapy and occupational therapy, supplemented with tailored, individualised interventions delivered by rehabilitation assistants either singly or in groups.
Study NCT05527262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive gaming therapy
Description: The treatment group will receive a minimum of 45 hours of active time on task over 3 weeks, 5 days a week (first and last day will involve the assessment procedures) to complete arm, hand and finger training (overseen by a physiotherapist). Patients will engage with MindPod Dolphin (shoulder/elbow) and other interfaces (hand/fingers) in a customised immersive game-based platform set.
Study NCT05526469 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior plane block
Description: patients in this group will receive ultrasound guided single shot serratus anterior plane block for pain control intra and postoperative
Study NCT05526469 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae plane blocks
Description: patients in this group will receive ultrasound guided single shot erector spinae plane block for pain control intra and postoperative
Study NCT05526469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Patients in both group will receive 0.5 ml/kg bupivacaine 0.25% injected locally in the muscle plane
Study NCT04869397 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Wharton's jelly-MSCs (WJ-MSC)
Description: The product is provided cryopreserved by NextCell Pharma. The cells are frozen in cryobags at a concentration of 2 × 107 cells/ml in 5% Human Serum Albumin (HSA) and 10% dimethylsulfoxide (DMSO). One cryobag contains one dose. The bags are frozen in a controlled rate freezer and directly transferred to -190 ºC for storage until the time of infusion.~Cryobags are thawed at bedside and diluted in 100 ml of saline prior to administration. Cells will be delivered at a rate of 5 million cells per minute over a total of 20 minutes.
Study NCT04869397 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride buffer supplemented with 5% HSA and 10% DMSO same volume and mode of administration as treatment group
Study NCT05667103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embotrap stent retriever
Description: Embotrap has a novel design of an open outer cage for clot capture and a closed inner channel for clot stabilization, with great thrombus fixation and anti-escape ability, to improve the successful recanalization rate and good prognosis of patients.
Study NCT05667103 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Solitaire FR, Trevo stent retriever without inner channel
Description: Other stent retriever without inner channel, such as Solitaire FR, Trevo, and other stent retrievers approved by FDA or NMPA.
Study NCT06415149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High power short duration ablation with 50 W
Description: Group 1 (n=95): pulmonary vein isolation for treatment of atrial fibrillation was performed with power of 50 watts in Ia subgroup (n=55) AI (ablation index) was 400-450 arbitrary units (au) for the posterior wall and 500-550 au for the anterior wall, in Ib (n=40) AI was 400-450 au for the posterior wall and 450-500 au for the anterior wall.
Study NCT06415149 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High power short duration ablation with 45 W
Description: Group 2 (n=90): Pulmonary vein islolation was performed at a power of 45 watts, in IIa subgroup (n=50) with target AI of 400-450 au for the posterior wall and 500-550 au for the anterior wall in IIb (n=40) AI of 400-450 au for the posterior wall and 450-500 au for the anterior wall.
Study NCT05521815 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coma arousal therapy
Description: early coma arousal therapy program in addition to selected physical therapy program (positioning, breathing exercise, passive movement of the four limbs).
Study NCT05521815 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Selected physiotherapy program
Description: selected physiotherapy program only (positioning, breathing exercise, passive movement of the four limbs).
Study NCT04217603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) device
Description: Use of a CPAP during a 6 minute walk test to maintain the airways open during the respiratory cycle
Study NCT04217603 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-continuous positive airway pressure (CPAP) device
Description: An enlarged air leak incorporated into the exhalation valve will be positioned between the mask and the CPAP tubing, allowing airflow resistance of the exhalation port to be almost eliminated by increasing its area, thereby virtually cancelling positive pressure. Also an orifice restrictor in the CPAP circuit will be connected between the CPAP unit and the tubing in order to load the blower with the same airflow resistance as in true CPAP.
Study NCT04024488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TI-CBT Intervention Arm
Description: TI-CBT teaches techniques and ways to manage distress through psychosocial health education, cognitive restructuring, and mastery of trauma, which refers to the process by which survivors of psychological trauma work through the traumatic experience in a meaningful way, and are able to move on with life. TI-CBT addresses both the trauma of learning one has HIV and the trauma associated with managing a chronic and stigmatized illness. The intervention highlights links between HIV and traditional gender roles, gender inequities, and gender based violence. Finally, the relaxation training teaches youth strategies to relax and these are integrated at the beginning and end of each session. TI-CBT Youth and Caregiver Intervention Manuals are distributed to sites for translation, backtranslation, and cultural adaptation in preparation for the Randomized Trial.
Study NCT04024488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Discussion Control Arm
Description: Each youth discussion control group session will be led by IYL and each caregiver discussion control group will be led by adult study staff. Discussion topics will be selected by youth and caregivers in the group as applicable. Discussion Control group session will take place at a separate time from TI-CBT youth group sessions in attempt to minimize contamination. To note, participant and caregiver group sessions are always held separately.
Study NCT05469945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compressive garments class II
Description: Daily wearing of compressive garments, especially during prolonged standing upright or strenuous activities.
Study NCT05276791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EMR
Description: Endoscopic mucosal resection, according to standard care
Study NCT05276791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ESD
Description: Endoscopic submucosal dissection, according to standard care
Study NCT04693793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Materials and Janssen Test
Description: Intervention-1- and Intervention-2-arm participants will receive educational materials duplicating what physicians would receive in the real-world market as they adopt the Janssen technology. These materials are comprised of a slide deck, a sample test report, and a frequently asked questions (FAQ) sheet.~Intervention 1 participants only will receive the Janssen test results whether they select it or not, and Intervention 2 participants will receive the Janssen test results only if they select it during the second round of case simulations.
Study NCT04909827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D-printed endocrown
Description: pulpotomy and restoration with 3D-printed microfilled hybrid composite endocrown
Study NCT04909827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zirconia crown
Description: pulpotomy and restoration with prefabricated zirconia crown
Study NCT05308797 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP block
Description: Preoperative, awake, bilateral, ultrasound-guided erector spinae plane block with 30 mL 0.25 % bupivacaine
Study NCT05308797 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CASP block
Description: Preoperative, awake, bilateral, ultrasound-guided combine serratus anterior plane block with 30 mL 0.25 % bupivacaine
Study NCT05509361 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK101 injection SC
Description: AK101 is supplied as 135 mg doses, provided in 1 mL prefilled syringes.
Study NCT06342947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-055009
Description: Softgel Capsule
Study NCT06342947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Softgel Capsule
Study NCT06268834 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood for zonulin level was drawn from the group.
Description: Serum zonulin levels were determined by taking 5 cc blood from the antebrachial veins of the patients.